STOCKHOLM, Nov. 7, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Institut Curie, spread over three radiotherapy centers, located in Paris, Orsay, and Saint-Cloud, France, has placed an order for the treatment planning system RayStation®*. Institut Curie is part of the French hospital network Unicancer, and the order was placed under the Unicancer 2019 Framework agreement.

RayStation will mainly support the Institut Curie Proton Therapy Center in Orsay, which is one of three proton centers in France, all of which are now equipped with RayStation.

STOCKHOLM, Oct. 21, 2024 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the third quarter of 2024 on November 8, 2024, at 10.00 am CET. The report will be published on November 8, 2024, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan Löf, founder and CEO, and Annika Blondeau Henriksson, interim CFO, will present the company's development in a webcast. After the presentation (held in English) there is the opportunity to ask questions.

STOCKHOLM, Oct. 16, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Institut de Cancérologie de Lorraine, Centre Jean Perrin, and Centre Hospitalier Universitaire de Limoges, have placed orders for the treatment planning system RayStation®* under the Unicancer 2019 Framework agreement.

Unicancer is a French hospital network exclusively specialized in oncology. It brings together 18 comprehensive cancer centers and two affiliated centers, spread across 22 hospitals in France. Annually, more than 600,000 patients are treated at a Unicancer center and across the network, 787 clinical trials are ongoing.

STOCKHOLM, Oct. 11, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce that the number of radiotherapy centers in China using RayStation®* for treatment planning now has passed 100. In terms of number of centers, China is RaySearch's third largest market after the US and Japan.

Since its launch in 2009, RayStation has been sold to more than 1,000 cancer centers in 44 countries. In the US and Japan, the system is used by more than 300 and 220 centers respectively. With the installation of RayStation at the China Japan Friendship Hospital in Beijing, RaySearch has reached an important milestone in China, where the number of centers using RayStation now exceeds 100.

STOCKHOLM, Oct. 10, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that GenesisCare UK has placed an order for the RayStation®* treatment planning system.

GenesisCare is the UK's leading independent cancer care provider, operating 14 specialist outpatient cancer centers. This order signifies the plan to fully replace its current Pinnacle radiotherapy treatment planning system with RayStation.

The advanced technology licenses acquired will support GenesisCare's dedication to delivering high precision advanced treatment techniques, enhancing their established adaptive radiotherapy capabilities. The RayStation software will continue to support remote planning across the GenesisCare UK network, where treatments for patients at any of their 14 centers are planned by dosimetrists and physicists nationally.

STOCKHOLM, Sept. 27, 2024 /PRNewswire/ -- RaySearch's founder and CEO, Johan Löf, has sold 150,000 Class B shares in RaySearch Laboratories AB (publ) on September 24, 2024. Johan Löf remains a long-term shareholder and after the transaction owns 5,443,084 Class A shares and 68,393 Class B shares, corresponding to 16.1 percent of the total number of shares and 52.8 percent of the total number of votes in the company.

Johan Löf, founder and CEO, RaySearch: "The sale is due to private financial reasons. I remain committed to the company with continued strong confidence in RaySearch's future. We are well positioned for continued growth, and I look forward to continuing to lead and develop RaySearch towards our strategic goals."

STOCKHOLM, Sept. 27, 2024 /PRNewswire/ -- RaySearch will be exhibiting its latest software innovations at ASTRO in Washington, D.C., September 29 – October 1. Participants can book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and the cloud-based oncology analytics system RayIntelligence® in RaySearchs's booth #327 during the event. Additionally, joint solutions between RaySearch and its industry partners Vision RT, GE Healthcare, Leo Cancer Care, and C-RAD will be presented.

STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Iridium Network in Belgium has treated its first patient using RaySearch's oncology information system RayCare®* together with a Varian TrueBeam®** linear accelerator. The treatment was successfully carried out on September 2, 2024.

Since its establishment in 2006, Iridium Network has grown to become the largest radiotherapy network in Belgium, providing highly specialized radiation oncology for three hospital networks in the larger region of Antwerp, as well as being a leading expertise center with an international reputation. In total, the network has ten TrueBeam linear accelerators, installed at four sites, treating more than 6,000 patients with radiation therapy each year.

STOCKHOLM, Aug. 21, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that the Connecticut Proton Therapy Center, Wallingford, Connecticut, USA, has placed an order for the oncology information system RayCare®*.

The Connecticut Proton Therapy Center will be the first of its kind in the state of Connecticut and is a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International. The center has selected RayCare and the IBA Proteus®ONE compact proton therapy system as its treatment platform.

STOCKHOLM, Aug. 16, 2024 /PRNewswire/ -- 

SECOND QUARTER (APRIL- JUNE 2024)      

Order intake SEK 290.3 M (239.2)Net sales SEK 318.9 M (239.5)Operating profit SEK 79.3 M (18.2)Profit after tax SEK 61.4 M (10.9)Earnings per share before/after dilution SEK 1.79 (0.32)Cash flow from operating activities SEK 154.6 M (67.2)Order backlog SEK 1,790.5 M (1,954.9) at the end of the period

HALF-YEAR (JANUARY- JUNE 2024)

Order intake SEK 528.8 M (445.8)Net sales SEK 576.1 M (469.6)Operating profit SEK 125.1 M (41.9)Profit after tax SEK 98.1 M (28.5)Earnings per share before/after dilution SEK 2.86 (0.83)Cash flow from operating activities SEK 321.9 M (220.9)